- Home
- PIII vs CLRB Comparison
PIII vs CLRB Comparison
Compare PIII & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | CLRB |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.9M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | PIII | CLRB |
|---|---|---|
| Price | $2.14 | $3.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | ★ 111.2K | 25.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.23 |
| 52 Week High | $11.30 | $10.19 |
Technical Indicators
Market Signals| Indicator | PIII | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 52.85 |
| Support Level | $1.96 | $3.07 |
| Resistance Level | $2.85 | $3.44 |
| Average True Range (ATR) | 0.33 | 0.20 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 46.24 | 90.48 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.